戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1          Aortic pulse-wave velocity measured vascular stiffness.
2  and whether this contributes to age-related vascular stiffness.
3 lated to pulse wave velocity as a measure of vascular stiffness.
4 w-density lipoprotein-dependent increases in vascular stiffness.
5 lastin and collagen, potentially influencing vascular stiffness.
6  that L-arginine has the potential to reduce vascular stiffness.
7  left ventricular systolic and diastolic and vascular stiffness.
8 f hypertension, endothelial dysfunction, and vascular stiffness.
9 thelial apoptosis, cell lysis, and increased vascular stiffness.
10 mic performance of the valve prosthesis, and vascular stiffness.
11 itable and associated with genes involved in vascular stiffness.
12 duction of ventricular systolic and arterial vascular stiffnesses.
13 1.49%; 95% CI: 0.93 to 2.04; p < 0.0001) and vascular stiffness (-0.529 m/s; 95% CI: -0.946 to -0.112
14 tension is predominantly systolic because of vascular stiffness; (2) it is associated with reduced ba
15                                              Vascular stiffness and blood pressure pulsatility are re
16                                              Vascular stiffness and calcification are markers of card
17 dependent proteins in vascular tissue affect vascular stiffness and calcification, which is associate
18  whether neonatal hyperoxia induces systemic vascular stiffness and cardio-renal dysfunction in adult
19                             Dysregulation of vascular stiffness and cellular metabolism occurs early
20  sodium restriction improves ventricular and vascular stiffness and function.
21 eletion of the Trxrd2 gene develop increased vascular stiffness and hypertrophy of the vascular wall.
22 hrombin generation, cardiac dysfunction, and vascular stiffness and identified incident AAAs during f
23 veral approaches can be considered to reduce vascular stiffness and improve vascular function in pati
24 sent a therapeutic target for age-associated vascular stiffness and isolated systolic hypertension.
25 ships among blood pressure and 3 measures of vascular stiffness and pressure pulsatility derived from
26 d is an independent contributor to increased vascular stiffness and vascular risk in this patient gro
27 of PH, pharmacologic modulation of pulmonary vascular stiffness and YAP-dependent mechanotransduction
28 ction, arrhythmic diseases, atherosclerosis, vascular stiffness, and cardiac and vascular injury link
29  such as aneurysm formation, arterial aging, vascular stiffness, and chronic venous disease, even tho
30  enrolled, change in noninvasive measures of vascular stiffness, and clinical events.
31 opment of vasodilator dysfunction, increased vascular stiffness, and elevated blood pressure at a ver
32 y prevents farnesylation of lamin A, reduces vascular stiffness, and extends survival in HGPS patient
33 r burdens of subclinical atherosclerosis and vascular stiffness, and with a lower risk of hypertensio
34 mary outcome was between-group difference in vascular stiffness (ascending aortic distensibility).
35                                  We assessed vascular stiffness at baseline, after 3 to 6 weeks of th
36 iminary evidence that lonafarnib may improve vascular stiffness, bone structure, and audiological sta
37 nically regulated by the increase in retinal vascular stiffness caused by overexpression of the colla
38 ammation, endothelial dysfunction, increased vascular stiffness, changes in vascular structure, and a
39 mal responses to flow and NTG, and increased vascular stiffness confined to the upper part of the bod
40             Intima-media thickness (IMT) and vascular stiffness have been shown to be independent pre
41        Furthermore, TG2 inhibition decreases vascular stiffness in aging rats.
42 ular remodeling, and associated increases in vascular stiffness in females.
43 al remodelling on vascular contractility and vascular stiffness in health and disease.
44 lieved to increase left ventricular (LV) and vascular stiffness, in part via cross-linking proteins.
45 on, whereas the risk factors associated with vascular stiffness include SLE-specific variables relate
46 d by obesity, hypertension and age-dependent vascular stiffness increase mechanical workload, which i
47                                  Measures of vascular stiffness increased significantly during the pe
48                                              Vascular stiffness increases with advancing age and is a
49                                     Baseline vascular stiffness, indexed by arterial pulse-wave veloc
50 asminogen activator inhibitor-1 with central vascular stiffness indices, and C-reactive protein with
51                                 As a result, vascular stiffness is a key driver of (chronic) human di
52                                              Vascular stiffness is a mechanical property of the vesse
53 he groups as a whole, mitigated increases in vascular stiffness measured by PWA (P = 0.0065) and redu
54 d postinfarction therapies, does not improve vascular stiffness measurements or ejection fraction and
55 cant change from baseline to 6 months in the vascular stiffness measurements or left ventricular ejec
56                    Baseline characteristics, vascular stiffness measurements, and left ventricular fu
57 rential influences of biological pathways on vascular stiffness measures.
58  (alpha diversity and taxa abundance) with 3 vascular stiffness measures: carotid-femoral (PWV), aort
59 st whether vitamin K supplementation reduced vascular stiffness (MRI-based aortic distensibility) or
60 TR, vitamin K supplementation did not reduce vascular stiffness or calcification over 1 year.
61   Vitamin K2 supplementation did not improve vascular stiffness or other measures of vascular health
62 ed no effect of vitamin K supplementation on vascular stiffness or vascular calcification measures.
63 osterone system activation with pan-arterial vascular stiffness, plasminogen activator inhibitor-1 wi
64      Pulse wave velocity (PWV), a measure of vascular stiffness, predicts cardiovascular mortality in
65 ain rates, suggesting borderline disease and vascular stiffness, respectively.
66          There was no impact of vitamin K on vascular stiffness (treatment effect -0.23 [95% CI -0.75
67 d atherosclerosis, which are major causes of vascular stiffness (VS).
68                                Concurrently, vascular stiffness was assessed using pulse wave velocit
69                                              Vascular stiffness was evaluated using simultaneous caro
70                                              Vascular stiffness was measured by carotid-femoral pulse
71 ns in human DNA repair genes and markers for vascular stiffness, which is associated with aging.
72 athways of inflammation, cardiac stress, and vascular stiffness, which partly overlapped with HFrEF.
73 , not appreciated previously, that increased vascular stiffness with aging is attributable not only t